ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- App-Based Training Module on Guiding Physicians' Prescription for Antibiotic Treatment of Gonorrhea: Cluster Randomized Controlled Trial.JMIR mHealth and uHealth · 2026Trial
- Plasmids inClinical microbiology reviews · 2026Review
- A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeae.Nature microbiology · 2026Article
- Resistance Patterns ofAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial susceptibilities ofCanada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- A new class of penicillin-binding protein inhibitors to address drug-resistantbioRxiv : the preprint server for biology · 2024Article
- Sexual health beliefs and prevention of sexually transmitted infections among cisgender women sex workers in Colombia.PloS one · 2024Article
- Antimicrobial resistance and molecular characteristics ofAccess microbiology · 2024Article
- Trends in sexually transmitted and blood-borne infections in China from 2005 to 2021: a joinpoint regression model.BMC infectious diseases · 2023Article
- Antimicrobial susceptibilities ofCanada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Review
- Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae.Microbiology spectrum · 2023Article
- Evolution, persistence, and host adaption of a gonococcal AMR plasmid that emerged in the pre-antibiotic era.PLoS genetics · 2023Article
- A comprehensive review for machine learning based human papillomavirus detection in forensic identification with multiple medical samples.Frontiers in microbiology · 2023Review
- Antimicrobial susceptibilities ofCanada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- The Natural History of Rectal Gonococcal and Chlamydial Infections: The ExGen Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Observational
- Impact of Alternative Growth Supplements on Antimicrobial Susceptibility Testing ofInfection and drug resistance · 2022Article
- Molecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment ofPharmaceutics · 2021Article
- Utility of MALDI-TOF MS for differentiation of Neisseria gonorrhoeae isolates with dissimilar azithromycin susceptibility profiles.The Journal of antimicrobial chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Progressively decreasing susceptibility of Neisseria gonorrhoeae to the antibiotics recommended for treatment has raised concerns about the public health threat of antibiotic resistant gonorrhea. This is not a new process, and the organism has reliably developed resistance to all modern antibiotics used for treatment since the dawn of the antibiotic era. The history of changing recommendations for gonorrhea therapy is complex, however, and has been influenced by diagnostic test methods and surveillance. Understanding the impact of these influences may provide insights into current approaches to address this reemerging public health challenge. We reviewed available methods for gonorrhea diagnosis, and public health recommendations for gonorrhea treatment. The literature review was supplemented by qualitative interviews with senior investigators whose research helped shape gonorrhea management strategies over the past 50 years. The process of development of antimicrobial resistance to the antibiotics widely used for treatment seems to be inexorable. Many currently voiced concerns are similar to those raised in the past. The public health threat of increasing antimicrobial resistance by N. gonorrhoeae has been amplified as a result of a smaller pipeline introducing new drugs for gonorrhea treatment. Improved methods for gonorrhea diagnosis have also repeatedly influenced appreciation of the burden of disease caused by N. gonorrhoeae. US Public Health Service leadership has also shaped and improved the management of this important public health problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.